222 results on '"Denkert, C."'
Search Results
2. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
3. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
4. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
6. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
7. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
8. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
9. Endoscopic full-thickness resection (eFTR) for the treatment of neuroendocrine tumors of the rectum: The new standard procedure?
10. Recurrence rate after (f)EMR of colon adenomas≥2 cm: A retrospective single-center analysis
11. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
12. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
13. Beurteilung der Schwingfestigkeit von Schrauben großer Durchmesser im Maschinenund Anlagenbau unter Berücksichtigung von Herstellungs- und Randschichteinflüssen
14. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
15. Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
16. Endoskopische Vollwandresektion (eFTR) zur Behandlung von neuroendokrinen Tumoren des Rektums: Das neue Standard-Verfahren?
17. Rezidivrate nach (f)EMR von Colonadenomen≥2 cm: Eine retrospektive Single Center Analyse
18. Endoskopische Vollwandresektion (eFTR) allein vs. Hybrid-eFTR zur Behandlung neoplastischer kolorektaler Läsionen: eine retrospektive Vergleichsstudie
19. 99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)
20. 208P Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: A subanalysis of the German brain metastases in breast cancer registry (BMBC)
21. 129P Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort
22. 167P Deep learning-based whole slide image analysis to predict sentinel node status in the INSEMA cohort
23. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
24. SA 3.2 Tumor microenvironment in early breast cancer
25. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
26. 106P Ultra low-coverage whole genome sequencing for precision oncology in solid tumors
27. HRD-Testung und BRCA1/2-Keimbahntestung in der klinischen Routine bei Patientinnen mit primärem Ovarialkarzinom
28. Long-term survival of HER2-positive breast cancer patients with brain metastases: subanalysis of the BMBC Registry
29. 168P Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
30. 68MO Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies
31. 269P Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry
32. 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
33. 200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa
34. 151P Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts
35. Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”
36. Eine mdm2 Genamplifikation ist mit Progression und Metastasierung des luminalen Mammakarzinoms im humanisierten Tumormausmodell (hPDX) assoziiert, sowie mit einem ungünstigen klinischen Verlauf der Erkrankung
37. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC Registry
38. 170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry
39. 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
40. 24P Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome
41. 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)
42. 12P Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients
43. 60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B
44. HRD-Testung und BRCA1/2-Keimbahntestung in der klinischen Routine bei Patientinnen mit primärem Ovarialkarzinom
45. ESD RESECTION OF COLRECTAL PEDUNCULATED POLYPS: FIRST RESULTS
46. ENDOSCOPIC FULL-THICKNESS RESECTION (EFTR) FOR EARLY COLORECTAL CARCINOMA (CRC) – A RETROSPECTIVE ANALYSIS OF 31 CONSECUTIVE CASES
47. Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients
48. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
49. PREcoopERA Window-of-Opportunity trial of giredestrant+/- triptorelin vs. anastrozole+triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.
50. Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer- LOBSTER.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.